Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19
Vinpocetine (VPN) is an alkaloid derivative of vincamine inhibits phosphodiesterase type 1 that increase cyclic guanosine monophosphate and cyclic adenosine monophosphate. VPN have anti-inflammatory and antioxidant effects with suppression release of pro-inflammatory cytokines. Moreover, VPN mitigat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-06-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.future-science.com/doi/10.2144/fsoa-2021-0099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153070801977344 |
|---|---|
| author | Hayder M Al-kuraishy Ali I Al-Gareeb Muyiwa Samuel Fageyinbo Gaber El-Saber Batiha |
| author_facet | Hayder M Al-kuraishy Ali I Al-Gareeb Muyiwa Samuel Fageyinbo Gaber El-Saber Batiha |
| author_sort | Hayder M Al-kuraishy |
| collection | DOAJ |
| description | Vinpocetine (VPN) is an alkaloid derivative of vincamine inhibits phosphodiesterase type 1 that increase cyclic guanosine monophosphate and cyclic adenosine monophosphate. VPN have anti-inflammatory and antioxidant effects with suppression release of pro-inflammatory cytokines. Moreover, VPN mitigates oxidative stress (OS) and inflammatory reactions through inhibition of mitogen-activated protein kinase (MAPK) signaling pathway. Therefore, VPN may decrease hyper-inflammation-induced acute lung injury in COVID-19 through modulation of NF-κB pathway. Taken together, VPN has pulmonary and extra-pulmonary protective effects against COVID-19 through mitigation of OS and hyperinflammation. In conclusion, VPN has noteworthy anti-inflammatory and anti-oxidant effects through inhibition of NF-κB/MAPK signaling pathway so, it may reduce SARS-CoV-2-induced hyper inflammatory and OS. |
| format | Article |
| id | doaj-art-dbf8e492331f4b2c80c345645ce777ff |
| institution | OA Journals |
| issn | 2056-5623 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-dbf8e492331f4b2c80c345645ce777ff2025-08-20T02:25:48ZengTaylor & Francis GroupFuture Science OA2056-56232022-06-018510.2144/fsoa-2021-0099Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19Hayder M Al-kuraishy0Ali I Al-Gareeb1Muyiwa Samuel Fageyinbo2Gaber El-Saber Batiha31Department of Clinical Pharmacology & Therapeutics medicine, College of Medicine, AL-Mustansiriyiah University, Baghdad, Iraq1Department of Clinical Pharmacology & Therapeutics medicine, College of Medicine, AL-Mustansiriyiah University, Baghdad, Iraq2Department of Pharmacology & Therapeutics, Faculty of Basic Clinical Sciences, University of Medical Sciences, Ondo City, Ondo State, PMB 536, Nigeria3Department of Pharmacology & Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Albeheira, 22511, EgyptVinpocetine (VPN) is an alkaloid derivative of vincamine inhibits phosphodiesterase type 1 that increase cyclic guanosine monophosphate and cyclic adenosine monophosphate. VPN have anti-inflammatory and antioxidant effects with suppression release of pro-inflammatory cytokines. Moreover, VPN mitigates oxidative stress (OS) and inflammatory reactions through inhibition of mitogen-activated protein kinase (MAPK) signaling pathway. Therefore, VPN may decrease hyper-inflammation-induced acute lung injury in COVID-19 through modulation of NF-κB pathway. Taken together, VPN has pulmonary and extra-pulmonary protective effects against COVID-19 through mitigation of OS and hyperinflammation. In conclusion, VPN has noteworthy anti-inflammatory and anti-oxidant effects through inhibition of NF-κB/MAPK signaling pathway so, it may reduce SARS-CoV-2-induced hyper inflammatory and OS.https://www.future-science.com/doi/10.2144/fsoa-2021-0099anti-inflammatoryanti-oxidant effectsCOVID-19hyper-inflammationoxidative stressphosphodiesterase inhibitor |
| spellingShingle | Hayder M Al-kuraishy Ali I Al-Gareeb Muyiwa Samuel Fageyinbo Gaber El-Saber Batiha Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19 Future Science OA anti-inflammatory anti-oxidant effects COVID-19 hyper-inflammation oxidative stress phosphodiesterase inhibitor |
| title | Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19 |
| title_full | Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19 |
| title_fullStr | Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19 |
| title_full_unstemmed | Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19 |
| title_short | Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19 |
| title_sort | vinpocetine is the forthcoming adjuvant agent in the management of covid 19 |
| topic | anti-inflammatory anti-oxidant effects COVID-19 hyper-inflammation oxidative stress phosphodiesterase inhibitor |
| url | https://www.future-science.com/doi/10.2144/fsoa-2021-0099 |
| work_keys_str_mv | AT haydermalkuraishy vinpocetineistheforthcomingadjuvantagentinthemanagementofcovid19 AT aliialgareeb vinpocetineistheforthcomingadjuvantagentinthemanagementofcovid19 AT muyiwasamuelfageyinbo vinpocetineistheforthcomingadjuvantagentinthemanagementofcovid19 AT gaberelsaberbatiha vinpocetineistheforthcomingadjuvantagentinthemanagementofcovid19 |